Mirum Pharmaceuticals, Inc. (MIRM) Form 10-Q — Aug 5, 2026
Mirum Pharmaceuticals reported Q2 2026 product sales, net of $176.2 million, up 38% year over year, led by LIVMARLI at $128.7 million (+46%). Six-month product sales reached $336.1 million. GAAP losses widened sharply: Q2 net loss was $67.2 million and the H1 net loss $857.4 million, driven by $742.7 million of acquired IPR&D charges largely tied to the January 2026 Bluejay Therapeutics acquisition of brelovitug for hepatitis delta. Stockholders' equity swung to a $10.4 million deficit at June 30, 2026.
Key figures
- Revenue
- 176243000
- Total Debt
- 769000000
- Revenue Yoy
- +37.9% (Q2 2026 product sales, net vs. Q2 2025)
- Total Assets
- 1044981000
- Cash Position
- 561300000
- Shares Outstanding
- 64932203
- Accumulated deficit
- 1524926000
- 2032 notes principal
- 690000000
- Q2 2026 livmarli sales
- 128721000
- Cash and cash equivalents
- 330728000
- H1 2026 product sales net
- 336125000
- Livmarli q2 yoy growth pct
- 46
- 2032 notes conversion price
- 138.94
- H1 2026 acquired iprd expense
- 742737000
- 2029 notes principal remaining
- 79038000
- Bluejay purchase consideration
- 771076000
Price after filing
Close on the filing date to close N calendar days later (from $104.33). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.